Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance
- J Michael Straughn, Jr, MD
J Michael Straughn, Jr, MD
- Division of Gynecologic Oncology
- University of Alabama at Birmingham
- Section Editors
- Barbara Goff, MD
Barbara Goff, MD
- Section Editor — Gynecologic Oncology
- Department Chair, Gynecologic Oncology
- University of Washington Medical Center
- Don S Dizon, MD, FACP
Don S Dizon, MD, FACP
- Section Editor – Gynecologic Oncology
- Head of Women's Cancers, Lifespan Cancer Institute
- Director of Medical Oncology, Rhode Island Hospital
- Associate Professor of Medicine, Warren Alpert Medical School of Brown University
Despite screening programs that have dramatically reduced the incidence of cervical cancer in the United States, cervical cancer is the fourth most common cancer in women worldwide . Squamous cell carcinoma (SCC) accounts for approximately 80 percent of cervical cancers, while adenocarcinoma accounts for 15 percent, and adenosquamous carcinoma for 3 to 5 percent; neuroendocrine or small cell carcinomas are rare. (See "Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis".)
Management and outcomes for women with nonmetastatic invasive cervical cancer depend upon the International Federation of Gynecology and Obstetrics (FIGO) stage of disease at diagnosis (table 1). In general, primary treatment for non-small cell cervical cancer (surgery or radiotherapy with or without chemotherapy) has a cure rate of approximately 80 to 95 percent in early-stage disease (stage I and nonbulky stage II disease) and approximately 40 to 60 percent for bulky stage II and stage III disease. A summary of survival rates by stage of disease according to FIGO data is presented in the following table (table 2) .
Posttreatment surveillance after primary curative therapy for cervical cancer is uniformly recommended, although its effectiveness is not well studied. The main goal of surveillance is early detection of those recurrences that might be amenable to potentially curative salvage therapy. This is most likely with isolated central pelvic recurrences.
The timing and location of recurrent disease following potentially curative treatment for cervical cancer, the published data on the effectiveness of various surveillance strategies, and recommendations for posttreatment surveillance are reviewed here. Staging and primary management of invasive cervical cancer, as well as the approach to women treated for cervical cancer, are discussed separately. (See "Management of early-stage cervical cancer" and "Management of locally advanced cervical cancer" and "Invasive cervical cancer: Staging and evaluation of lymph nodes" and "Invasive cervical adenocarcinoma" and "Overview of approach to cervical cancer survivors".)
PATTERNS OF RECURRENCE
For women who underwent curative-intent therapy for cervical cancer, the predominant site of disease recurrence is local (ie, at the vaginal apex) or regional (ie, pelvic sidewall). The risk of persistent or recurrent pelvic disease increases with more advanced initial disease stage (table 1). As an example, one series reported pelvic failure rates of 10, 17, 23, 42, and 74 percent among 322 women undergoing radiation therapy (RT) alone for stage IB, IIA, IIB, III, and IVA disease, respectively .To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (Accessed on January 15, 2014).
- Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S43.
- Perez CA, Grigsby PW, Camel HM, et al. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 1995; 31:703.
- Muram D, Curry RH, Drouin P. Cytologic follow-up of patients with invasive cervical carcinoma treated by radiotherapy. Am J Obstet Gynecol 1982; 142:350.
- Rintala MA, Rantanen VT, Salmi TA, et al. PAP smear after radiation therapy for cervical carcinoma. Anticancer Res 1997; 17:3747.
- Gerdin E, Cnattingius S, Johnson P, Pettersson B. Prognostic factors and relapse patterns in early-stage cervical carcinoma after brachytherapy and radical hysterectomy. Gynecol Oncol 1994; 53:314.
- Morice P, Deyrolle C, Rey A, et al. Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 2004; 15:218.
- Sartori E, Pasinetti B, Carrara L, et al. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol 2007; 107:S241.
- Fagundes H, Perez CA, Grigsby PW, Lockett MA. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1992; 24:197.
- Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350:535.
- Samlal RA, Van Der Velden J, Van Eerden T, et al. Recurrent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis. Int J Gynecol Cancer 1998; 8:78.
- Larson DM, Copeland LJ, Stringer CA, et al. Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 1988; 30:381.
- Krebs HB, Helmkamp BF, Sevin BU, et al. Recurrent cancer of the cervix following radical hysterectomy and pelvic node dissection. Obstet Gynecol 1982; 59:422.
- Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004; 22:872.
- Elit L, Fyles AW, Devries MC, et al. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009; 114:528.
- Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000; 78:187.
- Esajas MD, Duk JM, de Bruijn HW, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 2001; 19:3960.
- Ansink A, de Barros Lopes A, Naik R, Monaghan JM. Recurrent stage IB cervical carcinoma: evaluation of the effectiveness of routine follow up surveillance. Br J Obstet Gynaecol 1996; 103:1156.
- Duyn A, Van Eijkeren M, Kenter G, et al. Recurrent cervical cancer: detection and prognosis. Acta Obstet Gynecol Scand 2002; 81:759.
- Beadle BM, Jhingran A, Yom SS, et al. Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2010; 76:1396.
- Soisson AP, Geszler G, Soper JT, et al. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol 1990; 76:106.
- Hong JH, Tsai CS, Lai CH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:249.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).
- American College of Obstetricians and Gynecologists.. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas. Number 35, May 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 78:79.
- Chou HH, Wang CC, Lai CH, et al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys 2001; 51:442.
- Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.
- Chung HH, Kim SK, Kim TH, et al. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. Gynecol Oncol 2006; 103:165.
- Brooks RA, Rader JS, Dehdashti F, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009; 112:104.
- Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 2003; 55:907.
- Ryu SY, Kim MH, Choi SC, et al. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003; 44:347.
- Siva S, Herschtal A, Thomas JM, et al. Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer 2011; 117:3981.
- PATTERNS OF RECURRENCE
- Effect of mode of treatment
- Symptomatology and timing
- Prognosis in recurrent disease
- SURVEILLANCE STRATEGIES
- Benefit of surveillance
- - History and physical examination
- - Cervicovaginal cytology
- - Chest radiograph
- - CT scan
- - PET/CT scan
- - Other tests
- SOCIETY GUIDELINE LINKS
- SUMMARY AND RECOMMENDATIONS